Dabigatran vs enoxaparin for portal vein clot in cirrhosis
Treatments studied
Part of Digestive system clinical trials.
This trial compares two blood-thinning medications, dabigatran (a pill) and enoxaparin (a shot), to see which works better and is safer for people with cirrhosis who have a blood clot in the portal vein (the main vein to the liver). It may help prevent the clot from getting worse or causing complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have cirrhosis of the liver.
- You have a blood clot in the portal vein that was found within the last 6 months, is causing symptoms, or you are waiting for a liver transplant.
- You are not currently bleeding or at very high risk of bleeding (for example, no recent major surgery, no large stomach ulcers, no severe varices with red signs).
- Your liver function is not too poor (Child-Turcotte-Pugh score less than or equal to 10).
- You do not have liver cancer (hepatocellular carcinoma) or a clot caused by a tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether blood thinners (anticoagulants) are safe and effective for people with cirrhosis and a blood clot in the portal vein. It may also include people with liver cancer (HCC).
This study tracks people with liver cirrhosis to see how often portal vein thrombosis (a blood clot in the main vein to the liver) occurs and how it can be treated with blood thinners. It aims to improve care for those at risk of these clots.
This trial tests whether a newer type of blood thinner can safely prevent dangerous bleeding from enlarged veins in the food pipe (esophagus) in people with liver cirrhosis who also have blood clots in the portal vein. The goal is to reduce the risk of life-threatening bleeding while managing the clot.
This trial is testing whether a blood thinner called apixaban can treat a blood clot in the main vein to the liver (portal vein) that appeared more than a year after spleen surgery in people with cirrhosis. It compares apixaban to a low-dose aspirin to see if one works better with fewer side effects.
This study tests whether a blood thinner called apixaban can safely prevent dangerous bleeding in people with cirrhosis (liver scarring) who have portal hypertension (high blood pressure in veins leading to the liver). The goal is to see if it reduces bleeding risk without causing excessive bleeding.
This early study tests whether the blood thinner pills rivaroxaban and apixaban can be used safely in people with liver cirrhosis that is not too severe. It may help doctors understand the safest way to prevent or treat blood clots in this group.
Hear when a new Portal Vein Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.